Denture marking methods and induced stress.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A M Fletcher.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Esposito, R. G. (United Fruit Co., Norwood, Mass.), H. Greenwood, and A. M. Fletcher. Growth factor requirements of six fungi associated with fruit decay. J. Bacteriol. 83:-250-255. 1962.-A study of the growth factor requirements of representatives of six genera of fruit-rotting fungi has been made. Gloeosporium musarum, Nigrospora sphaerica, Thielaviopsis paradoxa, and Verticillium theobromae all required biotin for growth. Under certain conditions in nitrate medium, Fusarium roseum appeared to be partially dependent on biotin. T. paradoxa also required thiamine for growth. In addition to biotin, N. sphaerica required an unknown material contained in extracts of yeast. Twenty-one known growth factors were tested and found to be inactive. Thiamine inhibited the growth of F. roseum, apparently by stimulating the formation of ethanol. Biotin reversed the effect of thiamine on growth and ethanol formation.
The safety and efficacy of two devices in producing elevated temperatures in bulky deep tumours was evaluated in 11 patients with 12 tumours. Nine of 11 patients had pelvic tumours. Each patient was given a separate trial heating with the microwave annular phased microwave array system (APAS) and the radiofrequency concentric magnetic induction coil (MI), and evaluation was based upon paired comparison of power-limiting patient tolerance endpoints as well as intratumoural temperatures achieved. Toxicity was minimal with either device. On average, 66 per cent of intra-tumoural (IT) temperatures reached greater than 41 degrees C with the APAS, and 12 per cent of IT temperatures reached greater than 41 degrees C with the MI (P less than 0.001). Thirty-two per cent of IT temperatures were greater than 42 degrees C with the APAS, compared to 7 per cent with MI (P less than 0.001). Although the annular microwave array is more complex to use, it has a significantly higher likelihood of achieving temperatures in the therapeutic range near 42 degrees C in deep pelvic tumours than does the magnetic induction coil.
Forty-four patients were treated using the BSD-1000 Annular Phased Array between April 1983 and December 1986. There were 32 pelvic, nine abdominal, two extremity, and one thoracic sites treated. Mean tumour volume was 646 cc. Thirty-nine patients had concurrent radiation therapy, receiving a mean dose of 38 Gy. Mean average temperature was 41.0 +/- 1.4 degrees C. Most patients experienced local or systemic toxicity, requiring temporary treatment interruption in 33 patients, and termination of treatment in eight. Chronic complications were seen in four, but these were in patients receiving high total radiation doses as well. There were six complete and five partial responses. Among the 32 patients with pelvic tumours, mean tumour volume was 317 cc, mean radiation dose was 42 Gy, and mean average temperature was 41.3 +/- 1.2 degrees C. There were five complete and four partial responses. Achieving tumour temperatures greater than or equal to 42 degrees C with the annular array is difficult, due to both systemic and local toxicity. To improve clinical hyperthermia for thoracic, abdominal, and pelvic tumours, new technologies such as steerable phased array microwave systems; scanned, focused ultrasound; and permanently implantable thermoregulating ferromagnetic seeds, or new approaches such as using drugs to alter blood flow, or combining hyperthermia with antineoplastic drugs or biological agents, will be necessary.
Explore the source record for details and available documents.